ACEIs and ARBs and Their Correlation with COVID-19: A Review

被引：20

作者：

Shewasinad Yehualashet, Awgichew ^{[1
]}

Fentik Belachew, Teshome ^{[2
]}

机构：

[1] Debre Berhan Univ, Dept Pharm, Coll Hlth Sci, Pharmacol & Toxicol Unit, POB 445, Debre Berhan, Ethiopia

[2] Debre Birhan Hlth Sci Coll, Dept Pharm, Debre Birhan, Ethiopia

来源：

INFECTION AND DRUG RESISTANCE | 2020年 / 13卷

关键词：

coronavirus; COVID-19; ACEIs; ARBs; RENIN-ANGIOTENSIN SYSTEM; CONVERTING ENZYME 2; RECEPTOR BLOCKERS; CORONAVIRUS; INHIBITORS; METAANALYSIS; THERAPY; TMPRSS2; SARS;

D O I：

10.2147/IDR.S264882

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Although some animal studies suggested that the use of ACEIs/ARBs could contribute for the prevention and treatment of the effects of the COVID-19 infection, there are also contradictory scenarios indicating that their use may exacerbate the deleterious conditions of the infection. As a result of the paradoxical issue of using ACEIs/ARBs during COVID-19, it is still an area requiring extended investigation to prove. Additionally, a trial evidence of their efficacy and the possible benefit risk analysis of these conventional drugs during COVID-19 in connection with other comorbidities like hypertension, heart failure, and renal disease associated with diabetes should also be addressed.

引用

页码：3217 / 3224

页数：8

共 50 条

[21] Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort
Gian Paolo Anzola
Clara Bartolaminelli
Gina Alessandra Gregorini
Chiara Coazzoli
Francesca Gatti
Alessandra Mora
Dimitrios Charalampakis
Andrea Palmigiano
Michele De Simone
Alice Comini
Erica Dellaglio
Salvatore Cassetti
Maurizio Chiesa
Francesca Spedini
Patrizia d’Ottavi
Maria Cristina Savio
Internal and Emergency Medicine, 2020, 15 : 1477 - 1484
[22] ACEIs, ARBs decrease type 2 diabetes
不详
GERIATRICS, 2005, 60 (12) : 12 - +
[23] Controversy regarding ACE inhibitors / ARBs in COVID-19
Soria Arcos, Federico
Romero Puche, Antonio
Vicente Vera, Tomas
REVISTA ESPANOLA DE CARDIOLOGIA, 2020, 73 (06): : 516 - 516
[24] Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
Bertsimas, Dimitris
Borenstein, Alison
Mingardi, Luca
Nohadani, Omid
Orfanoudaki, Agni
Stellato, Bartolomeo
Wiberg, Holly
Sarin, Pankaj
Varelmann, Dirk J.
Estrada, Vicente
Macaya, Carlos
Gil, Ivan J. Nunez
HEALTH CARE MANAGEMENT SCIENCE, 2021, 24 (02) : 339 - 355
[25] The impact of the COVID-19 pandemic on adverse events associated with ACEIs and ARBs: a real-world analysis using the FDA adverse event reporting system
Qiu, Hui
He, Li
Zhou, Jianzhu
Feng, Zeying
Ye, Ling
Li, Tong
Huang, Xin
Huang, Longjian
Guo, Chengjun
Chen, Shaojun
Guo, Chengxian
EXPERT OPINION ON DRUG SAFETY, 2025,
[26] ACEI inhibitors and ARBs do not increase severity of COVID-19
Reactions Weekly, 2020, 1802 (1) : 5 - 5
[27] Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
Dimitris Bertsimas
Alison Borenstein
Luca Mingardi
Omid Nohadani
Agni Orfanoudaki
Bartolomeo Stellato
Holly Wiberg
Pankaj Sarin
Dirk J. Varelmann
Vicente Estrada
Carlos Macaya
Iván J. Núñez Gil
Health Care Management Science, 2021, 24 : 339 - 355
[28] ARE ARBS COMPARABLE TO ACEIS IN PATIENTS WITH MYOCARDIAL INFARCTION?
Kim, Chong-Jin
JOURNAL OF HYPERTENSION, 2016, 34 : E22 - E22
[29] Temporal variation, socioeconomic status, and out-of-hospital deaths as factors that influence mortality rates among hospitalized COVID-19 patients receiving ACEIs/ARBs
Aftab, Owais M.
Modak, Anurag
Patel, Jai C.
JOURNAL OF CLINICAL HYPERTENSION, 2022, 24 (04): : 519 - 520
[30] Mortality in COVID-19 patients treated with ACEIs/ARBs: Re-estimated meta-analysis results following the Mehra et al. retraction
Alamer, Ahmad
Abraham, Ivo
PHARMACOLOGICAL RESEARCH, 2020, 160

← 1 2 3 4 5 →